Smith & Nephew (SN) Receives a Buy from Kepler Capital
In a report released on May 6, Christophe dombu from Kepler Capital maintained a Buy rating on Smith & Nephew, with a price target of p1,462.00. The company’s shares closed yesterday at p1,117.50.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, dombu is an analyst with an average return of -7.3% and a 46.09% success rate. dombu covers the Healthcare sector, focusing on stocks such as Kuros Biosciences, Smith & Nephew, and Nyxoah.
In addition to Kepler Capital , Smith & Nephew also received a Buy from Bank of America Securities’s Julien Ouaddour in a report issued on May 6. However, yesterday, Barclays assigned a Hold rating to Smith & Nephew (LSE: SN).
Based on Smith & Nephew’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of p3.31 billion and a net profit of p342.47 million. In comparison, last year the company earned a revenue of p2.98 billion and had a net profit of p198 million
Based on the recent corporate insider activity of 74 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SN in relation to earlier this year.
Read More on GB:SN:
Disclaimer & DisclosureReport an Issue
- Roberts Reiterates Hold on Execution Risks and Mixed Segment Performance, Trimming Price Target to $32
- Smith & Nephew price target raised to 1,350 GBp from 1,300 GBp at Barclays
- Julien Ouaddour Reiterates Buy on Smith & Nephew, Maintains 1,600 GBp Price Target Amid Solid Growth Outlook and New $500M Buyback
- Smith & Nephew price target lowered to $32 from $35 at Canaccord
- Smith & Nephew announces evidence for Cartiheal Agili-C Cartilage Repair
